For relapsed multiple myeloma (MM) patients, allo-SCT is a possible treatment option, but recent data obtained using a nonmyeloablative (NMA) conditioning regimen are scarce. We retrospectively collected data from 38 relapsed MM patients who received a NMA allo-SCT from October 2001 to January 2008. In total, 18 patients (48%) were transplanted using a matched unrelated donor. The median follow-up is 2.3 years. In 16 patients (42%) the response improved and eight patients (21%) were rapidly progressive within 6 months after allo-SCT. In total, 15 patients (39%) were in CR after allo-SCT. The median PFS was 1.4 years (range, 0.1-4.9), and having a CR after allo-SCT or having chronic GVHD resulted in longer PFS. Median OS was 3.1 years (range, 0.2-7.2) and again having a CR after allo-SCT or chronic GVHD was associated with a better OS. Six patients (16%) have died from treatment-related diseases. These results indicate that NMA allo-SCT is a treatment option in relapsed MM patients and that results may be improved by strategies that enhance the CR rate after allo-SCT.
Introduction
Both the role and timing of allo-SCT in patients with multiple myeloma (MM) are not clearly defined. Although some studies have shown a survival benefit of performing a nonmyeloablative (NMA) allo-SCT in the first-line setting after autologous SCT (auto-SCT), others could not show a survival benefit compared with double auto-SCT. [1] [2] [3] More results of ongoing comparative studies (mostly donor vs no donor analyses) are eagerly awaited. The role of allo-SCT as part of first-line therapy has become even more disputable with the introduction of novel agents thalidomide, lenalidomide and bortezomib. These agents show very high responses rates and long PFS with less toxicity when compared with a NMA allo-SCT procedure. [4] [5] [6] [7] [8] However, as MM cannot be cured, almost all patients will eventually relapse. Consolidation of a second response to therapy with a NMA allo-SCT may be an attractive option, especially for younger patients who relapse within 3 years after auto-SCT. 9 However, there are no large series published on NMA allo-SCT in relapsed MM patients. 10, 11 A recent report by De Lavallade et al. 12 including 18 patients treated with a reduced-intensity allo-SCT suggested a potential benefit compared with the 'no donor' group. Therefore, we retrospectively analyzed our transplantation database for relapsed MM patients transplanted from October 2001 to January 2008 with both sibling and unrelated HLA-matched donors to evaluate toxicity, GVHD, response, PFS and OS, and to evaluate factors that may influence outcome in this patient group.
Materials and methods

Study design
All consecutive patients with relapsed MM, who had received a NMA allo-SCT from either their siblings or unrelated donors from October 2001 to January 2008 in the Department of Haematology of the University Medical Center (UMC) Utrecht, the Netherlands, were included in this retrospective study. Follow-up data from medical records were gathered until January 2009 to ensure a minimal followup of 1 year for patients who were alive. Patients were treated according to clinical protocols approved by the local ethics board and gave their informed consent.
HLA typing was performed on HLA class I (A, B and C) and HLA class II (DRB1, DQB1) molecules using both serology and molecularly techniques. Donors were considered suitable when at least 9 out of 10 HLA class I and II molecules matched.
Conditioning regimen and GVHD prophylaxis
The conditioning regimen consisted of low-dose TBI of 2 Gy only; fludarabine (30 mg/m 2 , i.v.) was additionally administered for 3 days to patients who had not undergone auto-SCT a minimum of 6 months earlier. Patients with a matched unrelated donor or with a sibling donor with one HLA mismatch or patients planned to receive preemptive donor lymphocyte infusions (DLI) after allo-SCT also received rabbit antithymocyte globulin (ATG, 2 mg/kg, Genzyme, Cambridge, MA, USA) for 4 days in the conditioning regimen.
Graft versus host disease prophylaxis consisted of CsA, 2 Â 4.5 mg/kg per day for 4-6 months and tapered thereafter, and mycophenolate mofetil, 45 mg/kg per day for 2-3 months. CsA doses were adjusted to achieve trough blood levels between 0.2 and 0.4 mg/mL and lowered in case of renal failure.
All patients received prophylaxis for pneumococcal, toxoplasmosis, Pneumocystis carinii and viral herpes infections consisting of co-trimoxazol (480 mg b.i.d.) and valacyclovir (500 mg b.i.d.) for a minimum of 1 year.
Clinical outcome, response and GVHD assessment Data were gathered on occurrence of acute and chronic GVHD, treatment-related mortality (TRM) and relapse. GVHD was graded according the standard criteria. 13, 14 Response was assessed according to the recent The International Myeloma Working Group criteria. 15 Donor lymphocyte infusions Donor lymphocyte infusion (DLI) was given in case of disease progression or relapse in patients without GVHD after withdrawal of immunosuppressive therapy. Starting in September 2006, all patients were included in a phase I/II study investigating the safety and efficacy of autologous DC vaccination combined with DLI in patients who were not in CR after allo-SCT and not responding to a first preemptive DLI. DLI doses ranged between 1 Â 10 5 and 1 Â 10 7 CD3 þ T cells per kg.
Statistics
Overall survival was defined as the time from SCT until death or last follow-up. PFS was defined as the time from SCT until progression or last follow-up. Probabilities of OS and PFS were calculated using the Kaplan-Meier method and log-rank test was used to compare survival curves between subgroups. Univariate Cox regression analysis was performed to determine the prognostic value of various variables for OS and PFS. TRM, defined as any nonrelapse mortality, as well as acute and chronic GVHD were estimated by using the 1ÀKaplan-Meier method. A P-value of p0.05 was considered significant. Calculations were performed using SPSS 15.0 (SPSS, Chicago, IL, USA).
Results
Patient and transplant characteristics
We identified 39 patients who received NMA allo-SCT for relapsed MM. One patient had a primary graft failure and is not included in the analysis. The remaining 38 patients have a median follow-up of 2.3 years (range, 0.2-7.2). Median age was 56 years (range, 36-68) and 32 patients (84%) were male ( Table 1) . Data on cytogenetics and b2 microglobulin at diagnosis were incomplete for proper analysis. A total of 33 patients (87%) had received an auto-SCT after high-dose melphalan (200 mg/m 2 ) treatment. The median time between initial diagnosis and allo-SCT was 3.3 years (range, 0.6-9.6) and the median time between diagnosis of relapse and allo-SCT was 7.7 months (range, 2.9-19.9). A total of 27 patients (71%) were transplanted after their first relapse and 11 (29%) after second or third relapse.
After relapse and before allo-SCT, all patients received induction treatment. This induction treatment was variable and consisted of VCR, adriamycin and dexamethasone in 14 patients, thalidomide-dexamethasone in 17 patients, bortezomib in 4 patients and lenalidomide-dexamethasone in 3 patients. In 15 (40%) patients, an auto-SCT was performed after the induction treatment and within 2-6 months after this auto-SCT, the allo-SCT was performed ('auto-allo').
Patients received a median of two (range, two to four) treatment lines before allo-SCT. Thalidomide had been given to 95% of patients as initial treatment or on relapse.
The conditioning regimen consisted of TBI only in eight patients; fludarabine was added in six cases and ATG was added to TBI and fludarabine in another 24 patients. In 18 patients (48%), stem cells from an unrelated matched donor were used. HLA matching was 10 out of 10 in 27 patients (72%), and 9 out of 10 in 11 (28%) patients.
Transplant outcome and survival
At the time of allo-SCT 3 patients were in CR, 11 in very good PR (VGPR), 23 in PR and 1 patient had a progressive disease. After allo-SCT, remission status improved in 16 patients (42%) without the use of additional chemotherapy. In this group of 16 patients, 12 achieved a CR (7 from PR and 5 from VGPR) and 4 patients who were in PR before allo-SCT achieved a VGPR.
In eight patients (21%), including the patient who was progressive before allo-SCT, but in none of the patients in CR, progression was detected within 6 months after allo-SCT while using immunosuppressive therapy. In one patient, a secondary plasma cell leukemia was diagnosed within 1 month after allo-SCT and he received only palliative care. One patient responded to lowering of only immunosuppressive drugs, in all other patients, this was combined with dexamethasone (1 patient), thalidomide (1 patient), bortezomib (2 patients) or lenalidomide (2 patients). In two patients, a DLI was also given. Six patients responded, including the progressive patient before allo-SCT. The other two patients, including the patient with secondary plasma cell leukemia, died from MM progression. The median PFS was 1.4 years (range, 0.1-4.9), and the median OS was 3.1 years (range, 0.2-7.2) ( Figure 1 , Table 2 ). Median PFS for 15 patients (39%) in CR after allo-SCT was 2 years; seven patients (18%) have not progressed or relapsed after allo-SCT. The median duration of remission in these seven patients is 4.1 years (range, 1.1-4.9) and five of them have a CR, one has VGPR and one patient has continuous PR. In total, 28 patients (74%) have progressed or relapsed after the allo-SCT.
The 3-year cumulative incidence of acute and acute lateonset GVHD grade II or higher was 24%, and the 3-and 4-year cumulative incidences of chronic GVHD were 28 and 38%, respectively, mostly consisting of extensive chronic GVHD of the skin and mouth ( Table 2) .
The estimated cumulative incidence of TRM was 8% at 1 year and 17% at 3 years. TRM was caused by infections (two patients, one sepsis eci and one endocarditis with Streptococcus bovis), GVHD (two patients) and lymphoproliferative disorders (one patient) and one patient died of cardiomyopathy due to interstitial fibrosis of the myocardium, possibly related to previous chemotherapy. DLI was given to 21 patients (55%). The indication for DLI was relapse in 16 patients, and half of them responded to DLI in combination with chemotherapy. In the other five patients, the indication for DLI was preemptive in the setting of a clinical phase I/II study.
Determinants of outcome
In a univariate analysis, we analyzed factors that could influence OS and PFS (Table 3 ). Owing to the small numbers, results must be interpreted with caution. Only the occurrence of chronic GVHD or reaching CR after allo-SCT was positively associated with OS (Figures 2a and 3a) . The use of ATG or having a HLA mismatch was negatively associated with OS.
The presence of GVHD and reaching CR after allo-SCT was also associated with a better PFS (Figures 2b and 3b) .
As relapse within 1 year after auto-SCT is considered as high-risk disease with a poor outcome, 16 we additionally analyzed 26 patients who had received auto-SCT as firstline therapy and relapsed thereafter. In total, 12 patients relapsed within 1 year and 14 beyond 1 year. There was no significant association with OS, but the presence of this poor prognostic factor was associated with an inferior PFS (P ¼ 0.05).
Discussion
Treatment of relapsed MM remains a challenge, even in the era of novel drugs. Although different drug treatment options are available, the duration of a second or third response is often limited, possibly due to acquired drug resistance or selection of more aggressive MM (sub) clones. Kumar et al. reported a median OS of only 17.1 months from initiation of second-line therapy after relapse, but this has improved with the introduction of the novel drugs to almost 30 months. [17] [18] [19] Allo-SCT offers an additional treatment option in these patients using the proven graft vs myeloma effect to control disease burden. 20, 21 In this retrospective analysis, we focused on relapsed MM patients treated with allo-SCT after a NMA conditioning regimen. The difference with other reports is the larger and mature data set consisting of only relapsed MM patients and the frequent use of a nonrelated donor. [22] [23] [24] [25] However, owing to the small numbers of patients, statistical analysis performed in the study must be interpreted with caution.
After allo-SCT, 16 patients (42%) improved the quality of their response, with 12 patients achieving a CR and 4 patients a VGPR. These responses were mostly seen after immunosuppressive therapy was withdrawn. Eight (21%) patients were progressive directly after allo-SCT.
The PFS for the entire group is 1.4 years and till now, with a median follow-up of 2.3 years, seven patients who are alive have not experienced progression or relapse. Five of these patients are in CR, and achieving CR after allo-SCT is also a positive prognostic factor for a better PFS for the entire cohort. Median OS was 3.1 years and is influenced by the TRM after allo-SCT, mainly consisting of GVHD and infections. The 1 year cumulative TRM was only 8% and the estimated cumulative incidence of TRM at 3 years was 17%, which compares favorably to transplant results in MM patients using myeloablative conditioning. 26, 27 As shown by others, also in the myeloablative setting, the occurrence of chronic GVHD and achieving a CR after allo-SCT were positively associated with both PFS and OS. [28] [29] [30] Because the occurrence of GVHD is difficult to control, improvement of PFS and OS may be possible by maintenance therapy initiated shortly after allo-SCT to prevent early relapse and improve the depth of response in this high-risk population. This strategy was not followed in this cohort of patients. Figure 3 (a) OS and (b) PFS after NMA allo-SCT for patients having chronic GVHD or patients who did not.
During the time period of this analysis, bortezomib became available in the Netherlands since 2004 and lenalidomide since 2006. These drugs are very effective after allo-SCT, although lenalidomide must be used with caution because of the potent immunostimulatory effects than can be seen after allo-SCT. 31, 32 The encouraging median OS of 43 years is certainly positively influenced by the use of these drugs, which were given to patients who relapsed after allo-SCT.
Antithymocyte globulin was used in the conditioning regimen in 24 patients (63%) because of the use of a HLA mismatched sibling donor or a matched unrelated donor to facilitate engraftment and diminish severe acute GVHD. Although ATG and HLA mismatching had no influence on PFS, there was a negative impact on OS. This suggests that the use of ATG influenced nonrelapse mortality. Indeed, the six patients who have died from TRM, except one, did receive ATG. However, owing to the different reasons for mortality in these five patients, no further conclusions can be made.
As this analysis is a retrospective database analysis, the patients are not representative for the general MM population, as being reflected, for example, by a high percentage of males. Therefore, a selection bias would have occurred in this analysis. However, a considerable proportion of patients can be considered to be at high risk, because they had a relapse within 1 year after auto-SCT. 16 Therefore, we think that even patients with high-risk disease in good performance might benefit from an allo-SCT in first relapse. Unfortunately, data regarding other risk factors such as b2 microglobulin and cytogenetics were not generally collected at diagnosis.
In conclusion, these data show the feasibility of NMA allo-SCT in relapsed high-risk MM patients, with the use of unrelated donors in almost half of the patients. Median OS was 3.1 years and PFS was 1.4 years, and the occurrence of chronic GVHD and CR after allo-SCT resulted in a better survival. To further improve these results, we suggest that a maintenance strategy to improve the depth of response starting soon after allo-SCT should be explored.
